Randomised clinical trial: safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ-12420), a novel potassium-competitive acid blocker, in healthy male subjects-Reference-Cited by-同舟云学术

Randomised clinical trial: safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ-12420), a novel potassium-competitive acid blocker, in healthy male subjects

Published:2019-08-22 Issue:7 Volume:50 Page:751-759
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Han Sungpil¹^ORCID,Choi Hee Youn²,Kim Yo Han²,Nam Ji Yeon³,Kim Bongtae³,Song Geun Seog³,Lim Hyeong-Seok²,Bae Kyun-Seop²

Affiliation:

1. Department of Clinical Pharmacology and Therapeutics, Seoul St. Mary’s Hospital, PIPET (Pharmacometrics Institute for Practical Education and Training), College of Medicine; The Catholic University of Korea; Seoul Korea

2. Department of Clinical Pharmacology and Therapeutics, Asan Medical Center; College of Medicine; University of Ulsan; Seoul Korea

3. CJ HealthCare Corporation; Seoul Korea

Funder

CJ HealthCare Corp, Seoul, Korea

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.15438/fullpdf

Reference24 articles.

1. Global Consensus G. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus;Vakil;Am J Gastroenterol,2006